Literature DB >> 8761717

Treatment of disseminated Mycobacterium avium complex disease: a clinician's perspective.

C A Benson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8761717     DOI： 10.1016/0923-2508(96)80198-7

Source DB:  PubMed          Journal:  Res Microbiol        ISSN： 0923-2508            Impact factor:   3.992


× No keyword cloud information.
  4 in total

1.  Effects of the Chinese traditional medicine mao-bushi-saishin-to on therapeutic efficacy of a new benzoxazinorifamycin, KRM-1648, against Mycobacterium avium infection in mice.

Authors:  T Shimizu; H Tomioka; K Sato; C Sano; T Akaki; S Dekio; Y Yamada; T Kamei; H Shibata; N Higashi
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

2.  Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Authors:  Irma A J M Bakker-Woudenberg; Wim van Vianen; Dick van Soolingen; Henri A Verbrugh; Michiel A van Agtmael
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Pulsed-exposure and postantibiotic leukocyte enhancement effects of amikacin, clarithromycin, clofazimine, and rifampin against intracellular Mycobacterium avium.

Authors:  L Horgen; A Jerome; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

4.  Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with a half-sized secretory leukocyte protease inhibitor or the nonsteroidal anti-inflammatory drug diclofenac sodium against Mycobacterium avium complex infection in mice.

Authors:  C Sano; T Shimizu; K Sato; H Kawauchi; S Kawahara; H Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.